Verition Fund Management LLC trimmed its position in Quanterix Co. (NASDAQ:QTRX – Free Report) by 19.6% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 14,271 shares of the company’s stock after selling 3,490 shares during the period. Verition Fund Management LLC’s holdings in Quanterix were worth $185,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently made changes to their positions in QTRX. FMR LLC boosted its holdings in Quanterix by 112.6% in the third quarter. FMR LLC now owns 30,242 shares of the company’s stock valued at $392,000 after acquiring an additional 16,020 shares during the last quarter. Algert Global LLC lifted its position in Quanterix by 75.9% during the 3rd quarter. Algert Global LLC now owns 137,833 shares of the company’s stock valued at $1,786,000 after purchasing an additional 59,496 shares during the period. Intech Investment Management LLC bought a new position in shares of Quanterix in the 3rd quarter valued at about $170,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Quanterix during the 3rd quarter worth approximately $500,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Quanterix during the third quarter worth approximately $258,000. 86.48% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Separately, TD Cowen raised their price objective on shares of Quanterix from $13.50 to $16.00 and gave the company a “hold” rating in a research note on Wednesday, November 13th.
Quanterix Trading Up 6.8 %
Shares of QTRX opened at $11.41 on Tuesday. The stock has a market cap of $437.90 million, a P/E ratio of -10.87 and a beta of 1.30. Quanterix Co. has a 1 year low of $10.28 and a 1 year high of $29.70. The stock’s 50-day moving average price is $12.48 and its two-hundred day moving average price is $13.19.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.
Featured Stories
- Five stocks we like better than Quanterix
- Buy P&G Now, Before It Sets A New All-Time High
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- Where to Find Earnings Call Transcripts
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- How to Start Investing in Real Estate
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Want to see what other hedge funds are holding QTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quanterix Co. (NASDAQ:QTRX – Free Report).
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.